Related Experiment Video
Updated: Jul 12, 2025
Modified Single-Loop Reconstruction for Pancreaticoduodenectomy
Published on: September 28, 2019
[Pancreatic cancer-screening or surveillance?]
Simon Sirtl1, Marlies Vornhülz2, Felix O Hofmann3
1Medizinische Klinik und Poliklinik II, LMU Klinikum, 81377, München, Deutschland. simon.sirtl@med.uni-muenchen.de.
Background:
Despite continuous improvement of diagnostic and therapeutic procedures, the number of new pancreatic ductal adenocarcinoma (PDAC) cases diagnosed annually almost equals the number of PDAC-related deaths. Prerequisite for curative treatment is a resectable tumor at the time of diagnosis. Individuals with genetic and/or familial risk profiles should therefore be screened and included in structured surveillance programs.
Objectives:
Description of the status quo and usefulness of current PDAC screening and surveillance concepts.
Methods:
A selective literature search of current national and international guidelines including underlying literature was performed.
Results:
Nearly half of pancreatic cancer cases are missed by currently available surveillance programs, even in high-risk cohorts. Magnetic resonance imaging and endoscopic ultrasound supplemented by CA19‑9 (± HbA1c) are not accurate enough to ensure robust earlier pancreatic cancer detection. Complementary biomarker panels will take on a crucial diagnostic role in the future.
